1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN
(
- Contribution to journal › Article
- 2022
-
Mark
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
(
- Contribution to journal › Article
-
Mark
A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues
(
- Contribution to journal › Article
- 2021
-
Mark
Loss of ret promotes mesenchymal identity in neuroblastoma cells
(
- Contribution to journal › Article
-
Mark
BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells
(
- Contribution to journal › Article
-
Mark
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
(
- Contribution to journal › Article
- 2020
-
Mark
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma
(
- Contribution to journal › Article
- 2018
-
Mark
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
(
- Contribution to journal › Article
- 2017
-
Mark
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligandindependent
(
- Contribution to journal › Article
- 2016
-
Mark
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
(
- Contribution to journal › Article